SCHEMBL10036082

SCHEMBL10036082

CCN1/C(=C/C(C)=C2\C(=O)N(c3ccc(S(=O)(=O)O)cc3)N=C2C)Sc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.45
▸ ALDH1A1 P00352 9/20 0.45
▸ HPGD P15428 4/20 0.45
▸ HTT P42858 2/20 0.45
▸ KAT8 Q9H7Z6 1/20 0.43
▸ MEN1 O00255 10/20 0.43
▸ KMT2A Q03164 10/20 0.43
▸ RAB9A P51151 5/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ NPC1 O15118 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ RECQL P46063 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11587183 1.00 MAPT (0.45) MAPTALDH1A1HPGDHTTKAT8
SCHEMBL11789680 0.85 MAPT (0.42) MAPTALDH1A1HPGDHTTKAT8
SCHEMBL10036143 0.84 KAT8 (0.49) MAPTALDH1A1HPGDHTTKAT8
SCHEMBL11040384 0.79 ALDH1A1 (0.45) MAPTALDH1A1HPGDHTTKAT8
SCHEMBL11040379 0.79 ALDH1A1 (0.45) MAPTALDH1A1HPGDHTTKAT8
SCHEMBL8580449 0.72 KMT2A (0.56) MAPTALDH1A1HPGDHTTMEN1
SCHEMBL11771211 0.69 KAT8 (0.48) MAPTALDH1A1HPGDHTTKAT8
SCHEMBL13576593 0.69 MAPT (0.66) MAPTALDH1A1HPGDHTTMEN1
SCHEMBL31531966 0.68 MAPT (0.76) MAPTALDH1A1HPGDHTTMEN1
SCHEMBL11119010 0.68 MAPT (0.76) MAPTALDH1A1HPGDHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 MAPT 43/4885ALDH1A1 2810/4885HPGD 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback